Andrew Tsai, an analyst from Jefferies, maintained the Buy rating on Annexon Biosciences (ANNX – Research Report). The associated price target remains the same with $10.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andrew Tsai has given his Buy rating due to a combination of factors that highlight the potential of Annexon Biosciences’ ANX005 for treating Guillain-Barré Syndrome (GBS). The company is preparing for a Biologics License Application (BLA) filing in the second half of 2025, following positive Phase III results in Southeast Asian patients. These results have shown comparability to a Western patient database, which could support regulatory approval.
Additionally, there is a precedent with the FDA approving Radicava for ALS based on similar foreign data, which strengthens the case for ANX005. The lack of approved GBS therapies in the U.S. may also lead to greater regulatory flexibility. Annexon’s proactive approach, including a forthcoming study in Western patients, further underlines their commitment to addressing any potential regulatory concerns.